Globe Newswire SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene ) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...\n more…
Zacks Investment Research Clene Inc. (CLNN) closed the last trading session at $5.65, gaining 24.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall...\n more…
Ticker Report Clene Inc. (NASDAQ:CLNN - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 158,100 shares, a...\n more…
Zacks Investment Research Clene Inc. (CLNN) closed the last trading session at $5.11, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street...\n more…
Ticker Report Clene (NASDAQ:CLNN - Free Report) had its price objective increased by HC Wainwright from $7.00 to $31.00 in a report released on Friday morning, Benzinga reports. They currently have a buy rating on...\n more…